Moderna announced that it has filed for marketing authorization in the United States, the European Union, Canada and Australia for its investigational seasonal influenza vaccine, mRNA‑1010, targeting adults 50 years and older.
The filing is a key milestone in Moderna’s strategy to diversify its revenue base as sales of its COVID‑19 vaccine have fallen sharply. The company has set a goal of achieving cash breakeven by 2028, and the launch of mRNA‑1010 is intended to provide a new, recurring revenue stream that can help offset the decline in pandemic‑era sales.
The global mRNA flu market is projected to reach $19.20 billion by 2032, and mRNA‑1010’s efficacy of 26.6 % in adults 50 + and 27.4 % in those 65 + positions it competitively against traditional egg‑based and recombinant vaccines. Moderna’s mRNA platform allows for rapid strain updates, giving it a potential speed advantage in responding to circulating influenza viruses.
Moderna is entering a crowded flu market that includes established players such as Sanofi and GSK. Its mRNA technology offers a distinct advantage in development speed and adaptability, and the company is also advancing a combination flu/COVID‑19 vaccine candidate, mRNA‑1083, which could further broaden its portfolio.
CEO Stéphane Bancel said the regulatory filings “represent an important opportunity to support Moderna’s continued growth in 2027 and beyond.” He emphasized the company’s confidence in the mRNA platform and its commitment to expanding into new therapeutic areas.
Investors welcomed the filing, viewing it as a concrete step toward new revenue streams and a diversification of Moderna’s product pipeline. The market reaction reflected confidence in the company’s long‑term growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.